IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Summary

The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition.

Timeline

Start

2024-08-21

Primary completion

2027-08-31

Completion

2029-08-31

Drugs

Indications